Shots:
- ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials
- ImaginAb will provide technical, clinical & regulatory support to Pfizer
- The collaboration follows the pre-competitive alliance b/w ImaginAb, Pfizer and other global companies focusing on the development of 89Zr CD8 ImmunoPET technology, signed in Oct 14, 2019
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post Pfizer Signs a License and Supply Agreement with ImaginAb for CD8 ImmunoPET Technology first appeared on PharmaShots.
